- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05230537
Eine maskierte, placebokontrollierte Studie zur Bewertung von Iptacopan bei altersbedingter Makuladegeneration
Eine randomisierte, von Teilnehmern und Prüfern maskierte, placebokontrollierte, multizentrische Proof-of-Concept-Studie zur Bewertung der Sicherheit und Wirksamkeit von LNP023 (Iptacopan) bei Patienten mit früher und mittlerer altersbedingter Makuladegeneration
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a multicenter, randomized, participant and investigator masked, placebo controlled, proof-of-concept study to assess the safety and efficacy of Iptacopan (LNP023) in participants with early to intermediate age-related macular degeneration in one eye and neovascular age-related macular degeneration in the other eye. All enrolled participants must have early/intermediate AMD in one eye, with at least one high risk optical coherence tomography (OCT) feature (study eye) and neovascular AMD in the other eye (fellow eye).
Participants who meet all of the eligibility criteria will be randomized at the Baseline/Day 1 visit in a 1:1 ratio into one of two treatment arms:
- Iptacopan (LNP023) oral capsules
- Placebo oral capsules Approximately 146 participants (73 per arm) will be treated worldwide.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Shanghai, China, 200080
- Novartis Investigative Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150001
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Novartis Investigative Site
-
-
-
-
-
Arecibo, Puerto Rico, 00612
- Emanuelli Research and Development Center LLC
-
-
-
-
California
-
Fullerton, California, Vereinigte Staaten, 92835
- Retina Consultants of Orange County
-
Huntington Beach, California, Vereinigte Staaten, 92647
- Salehi Retina Institute
-
Rancho Cordova, California, Vereinigte Staaten, 95670
- Martel Eye Medical Group
-
Sacramento, California, Vereinigte Staaten, 95841
- Retinal Consultants Medical Group Inc
-
Santa Barbara, California, Vereinigte Staaten, 93103
- California Retina Consultants
-
-
Colorado
-
Durango, Colorado, Vereinigte Staaten, 81303
- Southwest Retina Research Center
-
-
Florida
-
Deerfield Beach, Florida, Vereinigte Staaten, 33064
- Advanced Research LLC
-
Delray Beach, Florida, Vereinigte Staaten, 33484
- Retina Center Of South Florida
-
St. Petersburg, Florida, Vereinigte Staaten, 33711
- Retina Vitreous Associates of Florida
-
-
Indiana
-
Carmel, Indiana, Vereinigte Staaten, 46032
- Midwest Eye Institute
-
-
Louisiana
-
Metairie, Louisiana, Vereinigte Staaten, 70001
- Retina Associates New Orleans
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21209
- Retina Care Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Opthamalic Consultants of Boston
-
-
New Jersey
-
Bloomfield, New Jersey, Vereinigte Staaten, 07003
- Envision Ocular LLC
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Duke Eye Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97210
- Retina Northwest PC
-
-
Tennessee
-
Germantown, Tennessee, Vereinigte Staaten, 38138
- Charles Retina Institute
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78793
- Austin Research Center for Retina
-
Bellaire, Texas, Vereinigte Staaten, 77401
- Retina Consultants TX Rsrch Ctr
-
Dallas, Texas, Vereinigte Staaten, 75231
- Retina Foundation
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Texas Retina Associates
-
Houston, Texas, Vereinigte Staaten, 77030
- Retina Consultants of Houston PA
-
-
-
-
-
London, Vereinigtes Königreich, SE5 9RS
- Novartis Investigative Site
-
Southampton, Vereinigtes Königreich, SO16 6YD
- Novartis Investigative Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female participants ≥ 50 years of age
- Diagnosis of early or intermediate age-related macular degeneration (AMD) in the study eye as determined by the investigator on fundus examination
- Study eye (early/intermediate AMD eye) must have at least one high risk optical coherence tomography (OCT) feature (as defined by a central reading center).
- Diagnosis of neovascular AMD (nAMD) in the fellow eye as determined by the investigator.
- Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection are required prior to the start of the treatment with LNP023.
- If not received previously, vaccination against Haemophilius influenzae infection should be given, if available and according to local regulations.
Exclusion Criteria:
- History or current diagnosis of ECG abnormalities indicating significant safety risk, such as clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia and clinically significant second or third degree atrioventricular block (AV block) without a pacemaker.
- History of familial long QT syndrome or known family history of Torsades de Pointes
- History of stroke or myocardial infarction during the 6-month period prior to Baseline/Day 1, any current clinically significant arrhythmias, or any advanced cardiac or severe pulmonary hypertension
- History of end stage kidney disease requiring dialysis or renal transplant
- History of malignancy of any organ system
- History of solid organ or bone marrow transplantation
- History of recurrent meningitis or history of meningococcal infections despite vaccination
- History of immunodeficiency diseases, including a positive Human Immunodeficiency Virus test result at Screening
- Active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes or clinically relevant sensitivity to fluorescein dye as assessed by the Investigator.
- Evidence of cRORA or exMNV in the study eye based on multimodal imaging as determined by the central reading center.
- Participants who have current active TB as evidenced by clinical, radiographic and laboratory tests.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Iptacopan (LNP023)
Iptacopan (LNP023) oral use capsules |
oral capsules |
|
Placebo-Komparator: Placebo
Placebo matched to study drug, oral use capsules |
oral capsules |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imaging
Zeitfenster: Baseline/Day 1 through Month 24
|
OCT and other imaging will be performed using spectral domain OCT or swept source OCT machines |
Baseline/Day 1 through Month 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The incidence of ocular and non-ocular adverse events (AEs)
Zeitfenster: Baseline/Day 1 through Month 24
|
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. |
Baseline/Day 1 through Month 24
|
|
Change in Early Treatment Diabetic Retinopathy Study (ETDRS) (Standard Luminance) best corrected visual acuity (BCVA) scores in the early/intermediate AMD eye
Zeitfenster: Baseline/Day 1 through Month 24
|
Best corrected visual acuity (BCVA) will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in ETDRS low luminance visual acuity (LLVA) scores in the early/intermediate AMD eye
Zeitfenster: Baseline/Day 1 through Month 24
|
ETDRS low luminance visual acuity (LLVA) scores will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart. The number of letters read correctly, for each eye, will be recorded. Participants at sites in some countries may conduct BCVA testing using numerical charts rather than letter charts. |
Baseline/Day 1 through Month 24
|
|
Change in contrast sensitivity (CS) scores in the early/intermediate AMD eye
Zeitfenster: Baseline/Day 1 through Month 24
|
Pelli-Robson contrast sensitivity measurements will be performed using a Pelli-Robson contrast sensitivity wall chart and recording the number of correct letters read. |
Baseline/Day 1 through Month 24
|
|
Change in Standard luminance manifold contrast vision meter contrast sensitivity (MCVM-CS) scores in the early/intermediate AMD eye
Zeitfenster: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
|
Pharmacokinetics - concentrations of LNP023 related to trough samples
Zeitfenster: Baseline/Day 1 through Month 24
|
Bioanalytical determination of plasma LNP023 concentrations related to trough samples using a LC-MS (mass spectrometry) method. |
Baseline/Day 1 through Month 24
|
|
Change in low luminance manifold contrast vision meter (MCVM) contrast sensitivity scores in the early/intermediate AMD eye
Zeitfenster: Baseline/Day 1 through Month 24
|
MCVM contrast sensitivity measurements will be performed using an automated device that uses an adaptive algorithm to rapidly measure a contrast sensitivity function in 5-10 minutes. |
Baseline/Day 1 through Month 24
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Augenkrankheiten
- Empfindungsstörungen
- Erkrankungen der Netzhaut
- Netzhautdegeneration
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Makuladegeneration
- Geographische Atrophie
- Nasse Makuladegeneration
- Sehstörungen
- Iptacopan
Andere Studien-ID-Nummern
- CLNP023E12201
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .